company background image
UTH logo

United Therapeutics DB:UTH Stock Report

Last Price

€356.80

Market Cap

€15.9b

7D

4.5%

1Y

71.4%

Updated

27 Nov, 2024

Data

Company Financials +

United Therapeutics Corporation

DB:UTH Stock Report

Market Cap: €15.9b

UTH Stock Overview

A biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. More details

UTH fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance3/6
Financial Health6/6
Dividends0/6

United Therapeutics Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for United Therapeutics
Historical stock prices
Current Share PriceUS$356.80
52 Week HighUS$381.20
52 Week LowUS$192.30
Beta0.56
11 Month Change9.55%
3 Month Change11.74%
1 Year Change71.37%
33 Year Change112.38%
5 Year Change346.00%
Change since IPO1,882.22%

Recent News & Updates

Recent updates

Shareholder Returns

UTHDE BiotechsDE Market
7D4.5%-1.1%1.1%
1Y71.4%-18.8%7.2%

Return vs Industry: UTH exceeded the German Biotechs industry which returned -18.3% over the past year.

Return vs Market: UTH exceeded the German Market which returned 8.6% over the past year.

Price Volatility

Is UTH's price volatile compared to industry and market?
UTH volatility
UTH Average Weekly Movement4.7%
Biotechs Industry Average Movement6.6%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.9%
10% least volatile stocks in DE Market2.4%

Stable Share Price: UTH has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: UTH's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19961,168Martine Rothblattwww.unither.com

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin.

United Therapeutics Corporation Fundamentals Summary

How do United Therapeutics's earnings and revenue compare to its market cap?
UTH fundamental statistics
Market cap€15.93b
Earnings (TTM)€1.05b
Revenue (TTM)€2.61b

15.2x

P/E Ratio

6.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
UTH income statement (TTM)
RevenueUS$2.76b
Cost of RevenueUS$304.80m
Gross ProfitUS$2.45b
Other ExpensesUS$1.34b
EarningsUS$1.11b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)24.88
Gross Margin88.94%
Net Profit Margin40.31%
Debt/Equity Ratio6.6%

How did UTH perform over the long term?

See historical performance and comparison